Skip to content

Endocardial Pacing in On-table Non-responders in Cardiac Resynchronization Therapy

Non-Responders in Cardiac Resynchronization Therapy

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01193712
Enrollment
0
Registered
2010-09-02
Start date
2010-08-31
Completion date
2012-04-30
Last updated
2015-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Keywords

Electrophysiologic Techniques, Cardiac

Brief summary

The purpose of this study is to determine whether left ventricular endocardial pacing exhibits a greater acute hemodynamic response during biventricular pacing in patients who do not show this response to standard cardiac resynchronization therapy.

Detailed description

Cardiac resynchronisation therapy (CRT) with biventricular pacemakers and implantable cardiac defibrillators (ICD) has proven to be a valuable therapy in selected patients with systolic heart failure, ameliorating both morbidity and mortality. However, with current selection criteria and implant technique, about 20 to 30 % of patients remain non-responders. Non-responders might be due to failing selection criteria or methodology in casu echocardiography. However, an important number of non-responders may result of sub-optimal positioning of the left ventricular lead, remote from the site of delayed activation. Endocardial left ventricular stimulation may ameliorate the shortcomings of epicardial stimulation. The advantage of an endocardial approach is the absence of phrenic nerve stimulation which regularly complicates epicardial pacing, a more predictable pacing threshold and much less restriction to position the lead in the area of interest. Transseptal left ventricular endocardial pacing has already been used in patients in whom standard epicardial pacing was not applicable.

Interventions

PROCEDUREtemporary left ventricular endocardial pacing

a temporary pacemaker lead will be introduced through the aortic valve to evaluate the effect of left ventricular endocardial pacing. Four different pacing sites (basal and apical septal, basal and apical lateral) will be investigated with measurement of LV dP/dtmax. Afterwards, the endocardial pacing lead will be removed.

Sponsors

Catharina Ziekenhuis Eindhoven
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Age ≥18y 2. LVEF ≤35% 3. QRS-duration ≥0.12 seconds 4. NYHA functional class III or IV despite optimal medical therapy defined as use of angiotensin-converting enzyme inhibitors or angiotensin-II receptor blocker and beta-blockers unless they are not tolerated or contra-indicated 5. sinus rhythm or atrial fibrillation

Exclusion criteria

1. episode of acute heart failure ≤3 months 2. change in dosage of beta-blockers, angiotensin-converting enzyme inhibitors or angiotensin-II receptor blockers ≤3 months 3. unstable angina pectoris, acute myocardial infarction, percutaneous intervention or coronary bypass surgery ≤3 months 4. chronic atrial arrhythmias other than atrial fibrillation 5. any mechanical or biological valve prosthesis 6. atrial septal defect 7. right-to-left shunt 8. severe pulmonary hypertension (systolic pulmonary artery pressure \>90 mmHg) 9. uncontrolled arterial hypertension 10. known allergy to sulphur hexafluoride 11. end-stage renal or hepatic disease 12. inability to provide written informed consent 13. pregnancy or childbearing potential without use of birth-control measurements 14. general contra-indications to magnetic resonance imaging

Design outcomes

Primary

MeasureTime frame
change in acute hemodynamic response to CRT defined as an increase in LV dP/dtmax of ≥10% during left endocardial pacing compared to left epicardial pacing.baseline and 3 months

Secondary

MeasureTime frame
improvement in NYHA functional class ≥1baseline and 3 months
decrease in MLWHFQ of ≥9 pointsbaseline and 3 months
decrease in LVESV of ≥15%baseline and 3 months
increase in LVEF of ≥5%baseline and 3 months

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026